B A R O S
Skip to main content

Baros Surgery

Procedure Overview

  • Procedure Type: Restrictive + Malabsorptive
  • Surgery Duration: 1.5–2 Hours
  • Recovery Time: 2–3 Weeks
  • Approach: Laparoscopic
Single Anastomosis Sleeve Jejunostomy

Preserving Digestive Access While Maximizing Weight Loss

Single Anastomosis Sleeve Jejunostomy combines the benefits of sleeve gastrectomy with an intestinal bypass. A larger sleeve is created first, then 180–250 cm of the small intestine is attached to the lower portion of the stomach. This unique design preserves the normal digestive route while adding a malabsorptive component for enhanced weight loss.

What sets SASJ apart is its preservation of endoscopic access to the entire digestive tract — a critical advantage for long-term monitoring and management. This makes it an excellent option for patients who need both effective weight loss and the ability to undergo future diagnostic or therapeutic endoscopy.

SASJ is well suited for motivated patients across a range of BMI categories and eating patterns. The procedure promotes early fullness, sustained weight loss, and significant improvement in co-morbidities including diabetes, hypertension, and dyslipidemia, while maintaining digestive continuity.

01. Who It's For

SASJ is designed for patients who need a versatile procedure that combines effective weight loss with preserved digestive access for ongoing medical monitoring.

  • BMI greater than 35, or above 30 with co-morbidities
  • Morbidly obese patients motivated to stay active
  • Suitable for all eater types with poor quality of life
  • Patients who need ongoing endoscopic access post-surgery

02. How It Works

SASJ uniquely combines restriction and malabsorption while maintaining the natural digestive pathway for long-term clinical flexibility.

03. Expected Outcomes

SASJ delivers weight loss results comparable to OAGB while offering the added benefit of preserved endoscopic access. Expected outcomes include:

  • Effective excess weight loss comparable to OAGB (80–90%)
  • Significant improvement in diabetes and blood pressure
  • Preserved endoscopic access for future monitoring
  • Improvement in overall quality of life and mobility